Tango Therapeutics announced it will launch a pivotal Phase 3 study of vopimetostat (TNG‑462), a next‑generation PRMT5 inhibitor designed to exploit MTAP-deleted tumors, after positive Phase 1/2 signals in pancreatic ductal adenocarcinoma. The company concurrently closed a $225 million financing to fund the program. Early results showed objective responses and progression-free survival that compared favorably to historical chemotherapy, prompting Tango to pursue a registrational path in a highly unmet indication. Investors will watch whether the Phase 3 design confirms the early signal amid competitive PRMT5 programs from larger pharmas; Tango’s financing provides a runway to reach that inflection point.